



SimuGen
intuitive genomics

PRESS RELEASE

SimuGen Raises Venture Capital and Grant Funding

7 April 2009. London, UK

SimuGen, a pharmacogenomics company focused on predicting human toxicity early on in drug development, announced today that it was awarded the Biotechnology Commercialization Grant worth about US\$710,000 from the Malaysian Biotechnology Corporation just after it closed a Venture Capital financing round earlier in the year. Previous funding commitments were through Business Angel funding and the UK Government.

“Completing this financing in the current market conditions is a testament to the potential of SimuGen’s business, management and technology,” said Matthijs van Leeuwen, SimuGen’s Co-founder & COO. “The funding will be used to develop and launch our flagship product and to form partnerships for further market development”.

Brian O’Keeffe, CEO of SimuGen, commented, “For a long time now the pharmaceutical industry has struggled to meet the demands of both the product and stock markets. Candidate identification and optimisation quite rightly has come under close scrutiny by the various stakeholders. Innovation and the ability to create value through process intervention and product enhancement is key to SimuGen’s mission. The funding that SimuGen has recently acquired will certainly contribute enormously to realising these goals as well as contributing to further development of the life sciences in Malaysia”.

About SimuGen

SimuGen is a venture-backed pharmacogenomics company focused on predicting human toxicity early on in drug development. The company combines groundbreaking human cell and genomic modelling to produce high throughput screens for use alongside other early ADME testing. SimuGen's software explicitly answers three important questions that guide decisions around a lead compound:

1. what toxicities does it produce?
2. how toxic is it?
3. what could be done to make it less toxic?

The flagship product will predict a wide spectrum of human liver safety concerns, a leading problem stifling drug innovation. However, the basic approach can assess multiple-organ toxicities. SimuGen’s goal is to meet a major market gap that is not adequately addressed by current toxicogenomics – to accurately predict toxicity in the early stages of drug discovery/development.

Asia Pacific

Unit T108, Suite 7.01, Level 7
The Gardens South Tower
Mid Valley City
59200 Kuala Lumpur, Malaysia
T +603 2264 5200
F +603 2264 5201

Europe

Suite 405
International House
1- 6 Yarmouth Place
London W1J 7BU
United Kingdom
T +44 (0)2033 264 283

info@simugen-global.com | www.simugen-global.com